The Obesity Society

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Retrieved on: 
Tuesday, March 12, 2024
Research, Internal medicine, Overweight, Weill Cornell Medicine, The Obesity Society, Facial muscles, Obesity, Weight loss, SARM, Enobosarm, Education, Flyte, Metabolism, Patient, Weight, Pfizer, Obesity medicine, Davidoff, MD, Weill Cornell Medical Center, Jacobi Medical Center, Eli Lilly and Company, Bangladesh Technical Education Board, MOVE, Boehringer Ingelheim, Directory, Pharmaceutical industry

He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.

Key Points: 
  • He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.
  • Weight loss through any modality produces muscle loss, and there is an unmet need to minimize that in certain groups of patients in order to produce better quality weight loss.
  • In conjunction with a GLP-1 drug, enobosarm has the potential to deliver better quality weight loss while utilizing lower doses of the GLP-1 drug.
  • We are fortunate that Dr. Aronne and the other senior expert members of our Scientific Advisory Board will help guide the enobosarm development program.”

National Academy of Medicine Member New President of The Obesity Society

Retrieved on: 
Thursday, February 1, 2024
Bias, The Obesity Society, Medical school, Growth, University, Metabolism, Science, Obesity, Duke University Hospital, Division, Society, National academy, Patient, Inborn errors of metabolism, Columbia University, Wellness, Executive Committee, ARD, Obesity medicine, Harvard Medical School, Education, Health equity, Doctor of Philosophy, Health, Cornier, Cedars-Sinai Medical Center, Clinical research, Internal medicine

ROCKVILLE, Md. , Feb. 1, 2024 /PRNewswire/ -- A member of the National Academy of Medicine is the new president of The Obesity Society (TOS), the organization announced today.

Key Points: 
  • , Feb. 1, 2024 /PRNewswire/ -- A member of the National Academy of Medicine is the new president of The Obesity Society (TOS), the organization announced today.
  • He also co-directs the Atrium Health Wake Forest Baptist Weight Management Center, where he oversees medical weight management programs.
  • "I am honored to serve as president of TOS during such a transformative time in the field of obesity.
  • The Obesity Society (TOS) is the leading organization of scientists and health professionals devoted to understanding and reversing the epidemic of obesity and its adverse health, economic and societal effects.

The American Diabetes Association Releases the Standards of Care in Diabetes--2024

Retrieved on: 
Monday, December 11, 2023
Epidemiology, AID, Standard of care, Infection, PPC, Gestational diabetes, Diagnosis, CVD, Disability, Doctor of Philosophy, Mental health, Abridgement, Prediabetes, Diabetes, Knowledge, Webcast, NAFLD, RSV, Endocrinology, Fatty liver disease, Kidney disease, Cardiovascular disease, Fracture, Moyamoya disease, Society, Physician, Public, Hypoglycemia, Waist, Practitioner, PAD, Risk, Pharmacist, GIP, C-peptide, Artificial intelligence, Immunization, Conditional sentence, Section 4, Body mass index, Himawari (satellites), Classification, The Obesity Society, American Diabetes Association, Vaccine, Obesity, American College, Heart failure, COVID-19, Dietary supplement, Nursing, Landscape maintenance, Pharmaceutical industry, Medical device, Dentistry, MD

ARLINGTON, Va., Dec. 11, 2023  /PRNewswire/ -- Today, the American Diabetes Association® (ADA) released the Standards of Care in Diabetes—2024 (Standards of Care), a set of comprehensive and evidence-based guidelines for managing type 1, type 2, gestational diabetes, and prediabetes based on the latest scientific research and clinical trials. It includes strategies for diagnosing and treating diabetes in both youth and adults, methods to prevent or delay type 2 diabetes and its associated comorbidities like cardiovascular disease (CVD) and obesity, and therapeutic approaches aimed at minimizing complications and enhancing health outcomes.

Key Points: 
  • "The latest ADA guidelines present pivotal updates for health care professionals, ensuring comprehensive, evidence-based care for diabetes management.
  • "The ADA's Standards of Care ensures health care professionals, especially our primary care workforce, provide the best possible care to those living with diabetes."
  • The Standards of Care are critical to ensuring the improved treatment of diabetes, a chronic disease that requires continuous care through a well-informed and coordinated health care team.
  • Today, the Standards of Care in Diabetes—2024 is available online and is published as a supplement to the January 2024 issue of Diabetes Care® .

Doctors and Advocates Call for Better Testing and Labeling of Drugs for People with Obesity

Retrieved on: 
Tuesday, November 28, 2023
Drug, OAC, Obesity, Schizophrenia, Depression, Safety, Organization, Risk, Disease, Patient, The Obesity Society, FDA, Metabolism, Plasma protein binding, Society, Brexpiprazole, Education, Dietary supplement

The statement, which can be found at obesityaction.org/statement-drug-approval-labeling , calls for the U.S. FDA to close gaps in the testing and approval process for drugs intended for use by people with obesity for conditions other than obesity.

Key Points: 
  • The statement, which can be found at obesityaction.org/statement-drug-approval-labeling , calls for the U.S. FDA to close gaps in the testing and approval process for drugs intended for use by people with obesity for conditions other than obesity.
  • The statement also urges drug companies that are currently marketing drugs that have issues with safety or effectiveness for people with obesity to update their labeling immediately to provide appropriate usage instructions.
  • This means that every day, people with obesity are using FDA-approved drugs without full assurance that they are safe and effective for them.
  • Drugs that may present issues for people with obesity include drugs in many familiar categories, including emergency birth control, depression, and pain relief.

TOS Past Presidents Comment on SELECT Study Results

Retrieved on: 
Tuesday, November 14, 2023
Observation, Research, Feinberg School of Medicine, American Heart Association, Disease, Overweight, Cardiovascular disease, Patient, The Obesity Society, Conditional sentence, Health, Wellness, Harvard Medical School, Pennington Biomedical Research Center, Diabetes, Death, Cardiology, Body mass index, Medical education, SELECT, News, Hospital, Education, Safety, Pharmaceutical industry, Dietary supplement, Obesity, Marcelo Apovian, Medicine, Boston, MD

ROCKVILLE, Md., Nov. 14, 2023 /PRNewswire/ -- New findings show that the medication known as Wegovy® (semaglutide) can reduce existing heart disease in patients with obesity by 20%, according to a study co-authored by past presidents of The Obesity Society (TOS) and published in The New England Journal of Medicine.

Key Points: 
  • Apovian is professor at Harvard Medical School and co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, Boston, Mass.
  • I felt that the audience had confidence in the results because of the precision with which the study was executed.
  • To view a copy of the study titled "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," visit The New England Journal of Medicine website.
  • Combining the perspective of researchers, clinicians, policymakers and patients, TOS promotes innovative research, education and evidence-based clinical care to improve the health and well-being of all people with obesity.

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Rimonabant, NSCLC, Food, Biomarker, Doctor of Philosophy, CB1, Breast cancer, University of Virginia Cancer Center, SITC, The Obesity Society, Head, CSPC, FACP, Human, Therapeutic index, Cleavage, Yale School of Medicine, Society for Immunotherapy of Cancer, Mouse, DIO, Immunotherapy, University, Hand, Investment, Patient, Monoclonal antibody, Food and Drug Administration Amendments Act of 2007, Plasma, Conference, Liraglutide, Development, ADC, Brain, Insulin resistance, Society, AACR, IND, Manuscript, Poster, MMAE, Semaglutide, Tumor microenvironment, Carcinoma, Mab, Neck, Medical imaging, Vaccine, Soft drink, Pharmaceutical industry, Corbus, MD, Obesity

“The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Finally, we presented the first ever comprehensive data on CRB-913, our highly peripherally restricted cannabinoid type-1 receptor (CB1) inverse agonist.
  • Early clinical experience will be shared in Q1 2024, which will coincide with the initiation of a U.S./EU trial by Corbus.
  • Corbus presented two posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held on November 1 - 5, 2023.

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Retrieved on: 
Monday, October 23, 2023
Plasma, DSM-IV codes, C-peptide, BMI, Obesity, GIP, The Obesity Society, MAD, SAD, Pharmacokinetics, Lipid, Clinical trial, Safety, Overweight, Therapy, Patient, Human, SAN, Pharmaceutical industry, Vikings

SAN DIEGO, Oct. 23, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is in development for the potential treatment of various metabolic disorders such as obesity. Viking expects to report data from the study in the first half of 2024.

Key Points: 
  • VK2735 is in development for the potential treatment of various metabolic disorders such as obesity.
  • The Phase 2 VENTURE trial is a randomized, double-blind, placebo-controlled study intended to evaluate the safety, tolerability, pharmacokinetics, and weight loss efficacy of VK2735, administered subcutaneously, once weekly.
  • Due to heightened clinician and patient interest, the trial's enrollment size was increased to 176 from the original target.
  • The majority of observed adverse events (98%) in the Phase 1 trial were reported as mild or moderate.

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

Retrieved on: 
Tuesday, October 17, 2023
DIO, Partnership, Plasma, Morning Star, Rimonabant, Insulin resistance, Manuscript, Human, Weight loss, CB1, Mouse, The Obesity Society, Conference, Dietary supplement, Pharmaceutical industry, Tirzepatide, Semaglutide, Obesity, Liraglutide

“These data point to the potential of CRB-913, both as a monotherapy in combination with incretin therapies,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “These data point to the potential of CRB-913, both as a monotherapy in combination with incretin therapies,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • CRB-913 demonstrated markedly enhanced plasma exposure and markedly reduced brain levels compared to the first generation CB1 inverse agonist rimonabant.
  • Concomitantly, improvements were observed in body fat content, leptinemia, insulin resistance, liver triglycerides, liver fat deposits and liver histology.
  • Investigators concluded that CRB-913, in combination with incretin analogs, could potentially deliver meaningful improvements in obesity and related conditions.

Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

Retrieved on: 
Monday, October 16, 2023
NYSE, Weight, Energy, Poster, Obesity, Weight loss, MD, Body composition, The Obesity Society, Diet-induced obesity model, Semaglutide, DSM-IV codes, Waist, Disease, Overweight, Leptin, Myostatin, Insulin, Overalls, Fast food, Dietary supplement

NEW HAVEN, Conn., Oct. 16, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), announced the presentation of preclinical data demonstrating the ability of taldefgrobep alfa to significantly reduce fat mass while increasing lean mass in an obese mouse model. Separately, data supporting the correlation between change in waist circumference and change in total body weight among adults living with overweight and obesity treated with approved anti-obesity medications were reported. Both sets of data were presented on October 15, 2023 at The Obesity Society's annual ObesityWeek conference held in Dallas, TX.  

Key Points: 
  • - Taldefgrobep monotherapy significantly reduced fat and increased lean muscle mass in an obese mouse model; potential body composition changes relevant to individuals living with overweight and obesity.
  • NEW HAVEN, Conn., Oct. 16, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), announced the presentation of preclinical data demonstrating the ability of taldefgrobep alfa to significantly reduce fat mass while increasing lean mass in an obese mouse model.
  • Both sets of data were presented on October 15, 2023 at The Obesity Society's annual ObesityWeek conference held in Dallas, TX.
  • Taldefgrobep's differentiated mechanism offers the potential for a meaningful reduction in fat mass, the primary pathogenic tissue in obesity, while increasing lean mass.

Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023

Retrieved on: 
Tuesday, October 10, 2023
BMI, DSM-IV codes, Obesity, Plasma, Kay Bailey Hutchison Convention Center, GIP, MAD, Therapy, SAD, Pharmacodynamics, Clinical trial, C-peptide, The Obesity Society, Pharmaceutical industry, Vikings, Tolerability

SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that data from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735 will be highlighted as part of an oral presentation at ObesityWeek 2023, the annual meeting of The Obesity Society. VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders such as obesity. ObesityWeek 2023 is being held October 14-17, 2023, at the Kay Bailey Hutchison Convention Center in Dallas, Texas.

Key Points: 
  • VK2735 is a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors in development for the potential treatment of various metabolic disorders such as obesity.
  • ObesityWeek 2023 is being held October 14-17, 2023, at the Kay Bailey Hutchison Convention Center in Dallas, Texas.
  • The oral presentation will provide an overview of previously reported results from Viking's Phase 1 SAD/MAD study of VK2735 in healthy volunteers with a BMI ≥30.
  • In addition, new findings related to the impact of VK2735 on subjects' liver fat content and plasma lipid levels will be reported.